Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose general health and ability to carry out daily activities is rated at a good level (scored 0 or 1 on a standard health scale), with no worsening in the 2 weeks before starting the trial
- People whose organs (such as kidneys and liver) are functioning adequately
- People who have been confirmed by laboratory testing to have colon or rectal cancer that cannot be removed by surgery, or that has spread to other parts of the body (this applies to one group in the trial, called Cohort A)
- People who have been confirmed by laboratory testing to have prostate cancer (this applies to a second group in the trial, called Cohort B)
Who may not be able to join:
- People who have had another cancer (other than the one being studied in this trial) that has grown or needed active treatment in the past 24 months — though certain treated skin cancers or early-stage cancers that were fully removed with no signs of return may be acceptable
- People who have had major surgery within 28 days before starting the trial
- People who have had significant bleeding or a strong tendency to bleed within the past month before starting the trial
- People who have had a serious infection within 4 weeks before starting the trial
- People who have cancer that has spread to the brain or central nervous system and has not been treated, or where that spread has gotten worse
- People who currently have, or have previously had, a lung condition called interstitial lung disease or pneumonitis that required high-dose steroid treatment
- People who have a history of an autoimmune disease (where the immune system attacks the body) that required ongoing medical treatment within the 2 years before screening
- People who have taken immune-suppressing medications within 30 days before starting the trial, or who need to take them long-term — though low-dose steroids at a small daily amount may be permitted (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 877-379-3718
Australian sites
877-379-3718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with adverse events (AEs), Serious AEs (SAEs), AE of special interest (AESIs) and AEs leading to dose modifications; Number of participants with AEs, SAEs, AESIs, and AEs leading to dose modifications by severity; Number of participants with dose limiting toxicities (DLTs); Number of participants with clinically significant changes in Vital Signs, Body Weight, Laboratory Tests [Hematology, Clinical Chemistry, Urinalysis], Cardiac Function [ECG], and Eastern Cooperative Oncology Group (ECOG) performance status
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.